儿童、青少年及青年脑膜瘤分子工具评估:神经肿瘤学需全生命周期精准化
研究分析1568例脑膜瘤(含18例儿童、195例青少年及青年和1355例成人)的DNA甲基化与临床数据,评估现有分子分类与复发预测工具在不同年龄组的表现。儿童及青少年和青年(P/AYA)肿瘤的侵袭性分子分组和染色体臂缺失频率显著低于成人,成人训练的复发预测模型在P/AYA中失效(AUC 0.57),年龄特异性重训练后提升(AUC 0.79,P=0.00054)。1p缺失在P/AYA组内仍具预后意义。
要点
- 成人训练的脑膜瘤复发预测模型在P/AYA患者中区分度差(AUC 0.57),需年龄特异性建模。
- P/AYA脑膜瘤的侵袭性分子分组及1p、6q、14q染色体臂缺失频率显著低于成人。
- 1p缺失在P/AYA组内仍保留预后价值,支持其临床实用性。
核心结论
- 成人为主队列开发的分子工具因生物学差异和模型开发排除年轻患者,无法推广至P/AYA脑膜瘤患者。
- 需建立年龄特异性分子框架并将P/AYA人群纳入精准神经肿瘤学研究,以实现全生命周期公平医疗。
研究设计与样本
- 回顾性分析1568例脑膜瘤的DNA甲基化与临床数据,包括18例儿童(<15岁)、195例AYA(15-39岁)和1355例成人(>39岁)。
- 将儿童与AYA(P/AYA)肿瘤合并后与成人肿瘤比较分子分类器、复发预测器性能及染色体拷贝数改变差异。
主要发现
- 组织学分级在队列间相当,但P/AYA肿瘤的侵袭性分子分组和1p、6q、14q染色体臂缺失频率显著更低。
- 成人训练的复发预测器在P/AYA人群中失效,AUC为0.57,尽管评分分布相似。
- 采用相同分析框架在年龄特异性队列重训练模型后性能提升,AUC达0.79,并有效分层无进展生存期(P=0.00054)。
- 1p缺失在P/AYA组内仍具预后意义。
临床怎么用
- 对P/AYA脑膜瘤患者不应直接套用成人训练的分子复发预测模型,需警惕其区分度不足。
- 1p缺失可作为P/AYA脑膜瘤的预后标志物,支持其临床实用价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adolescent and young adult (AYA) patients remain underrepresented in neuro-oncology research. Despite being the second most common primary brain tumor in this population, meningiomas have not been studied using age-specific molecular analyses. DNA methylation-based classification and prognostic tools have transformed meningioma care. This study aimed to evaluate the performance of these tools across age groups. METHODS: We analyzed 1,568 meningiomas with DNA methylation and clinical data, including 18 pediatric patients (<15 years), 195 AYA patients (15-39 years), and 1,355 adult patients (>39 years). Pediatric and AYA (P/AYA) tumors were combined and compared with adult tumors. The performance of established molecular classifiers and recurrence predictors, as well as differences in chromosomal copy number alterations were compared across age groups. RESULTS: While histologic grading was comparable between cohorts, P/AYA tumors displayed significantly fewer aggressive molecular groups and lower frequencies of chromosomal arm losses, including 1p, 6q, and 14q. The adult-trained recurrence predictor failed in the P/AYA population (AUC 0.57), despite similar score distributions. Retraining the model on an age-specific cohort using an identical analytic framework improved performance (AUC 0.79) and enabled effective stratification of progression-free survival (P = 0.00054). Importantly, 1p loss retained prognostic significance within the P/AYA group, supporting its clinical utility. CONCLUSIONS: Molecular tools developed in adult-dominant cohorts do not generalize to younger patients due to both biological divergence and exclusion from model development. These findings underscore the need for age-specific molecular frameworks and highlight the imperative of including P/AYA populations in precision neuro-oncology research to ensure lifespan-equitable care.
引用
- Yefet LS, Landry AP, Wang JZ, et al. Assessment of molecular tools in pediatric, adolescent, and young adult meningioma highlights the need for lifespan precision in neuro-oncology. Neuro Oncol. 2026. PMID: 41206747. doi:10.1093/neuonc/noaf252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。